Indivior Pharmaceuticals, Inc 6-K, filed Sep 29, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-09-29
For: 2023-09-29
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on September 29, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: September 29, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: September 29,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
September 29, 2023
Board Committee Changes
Indivior PLC (the "Company") (LSE/NASDAQ: INDV) announces the
following changes to the structure and composition of its Board
Committees effective October 1, 2023. These changes are designed to
fully align and support Indivior's key strategic
priorities:
● The Nomination & Governance Committee has been
renamed the Compliance, Ethics &
Sustainability Committee and will have responsibility for the
oversight of the Group's Global Integrity and Compliance Program
and approach to ethical, responsible and sustainable conduct. Mark
Stejbach has been appointed as a member and Chair of this
Committee.
● The nomination-related responsibilities currently
undertaken by the Nomination & Governance Committee will be
transferred to a new Nomination
Committee which will have
oversight of Board and Committee composition and succession
planning. This Committee comprises Graham Hetherington as Chair and
all Non-Executive Directors.
● The Science & Policy Committee has been
renamed the Science
Committee. This Committee has
oversight of the Group's R&D strategy and pipeline development.
Policy matters, which previously fell under this Committee's remit,
will now become part of the Board's remit. There are no changes to
the membership of this Committee.
● The Audit Committee has been renamed
the Audit & Risk
Committee to better
reflect the role it plays in the oversight of internal control and
risk management activities. There are no changes to the membership
of this Committee.
● As previously announced, Jo Le Couilliard has been
appointed as Chair of the Remuneration
Committee. In addition, Barbara
Ryan has been appointed as a member of this
Committee.
Graham Hetherington, Chair, said 'These changes to the
structure and composition of the Committees reflect our active
evaluation and optimization of Board expertise to support
Indivior's strategy to create long-term value for stakeholders.
They reflect our continued focus on developing innovative
treatments that meet patient needs, conducting our business with
the highest integrity and our commitment to
sustainability'.
As previously announced, Daniel J. Phelan, Senior Independent
Director and Chair of the Remuneration Committee, and Lorna Parker,
Non-Executive Director, will step down from the Board on September
30, 2023. Also as previously announced, Juliet Thompson has been
appointed as Senior Independent Director with effect from October
1, 2023.
For completeness, membership of all of the above Committees with
effect from October 1, 2023, is set out below:
Audit & Risk Committee
Juliet Thompson (Chair)
Joanna Le Couilliard
Barbara Ryan
Mark Stejbach
Compliance, Ethics & Sustainability Committee
Mark Stejbach (Chair)
Graham Hetherington
Jerome Lande
Tom McLellan
Juliet Thompson
Nomination Committee
Graham Hetherington (Chair)
Peter Bains
Jerome Lande
Joanna Le Couilliard
Tom McLellan
Barbara Ryan
Mark Stejbach
Juliet Thompson
Remuneration Committee
Joanna Le Couilliard (Chair)
Peter Bains
Graham Hetherington
Barbara Ryan
Science Committee
Peter Bains (Chair)
Tom McLellan
Barbara Ryan
Mark Stejbach
This announcement is made pursuant to Listing Rule
9.6.11.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United
States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in
39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn
by visiting www.linkedin.com/company/indivior.
Contact
Jason Thompson
Vice President, Investor Relations
Indivior PLC
+1 804 402 7123
jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Indivior PLC
+1 804 263 3978
timothy.owens@indivior.com
-ends-